SOUTH SAN FRANCISCO, Calif., April 20 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated announced today that it will report first quarter 2006 results on Thursday, April 27, 2006 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 p.m. Eastern Time to discuss operational and financial results and the Company’s outlook for the future.
The conference call will be simultaneously webcast and can be accessed in the Investor Relations section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call is also accessible via telephone to investors, members of the news media and the general public by dialing either 866-999-CYTK (2985) (United States and Canada) or 706-679-3078 (International) and typing in the passcode 7704837.
An archived replay of the webcast will be available via Cytokinetics’ website until May 27, 2006. The replay will also be available via telephone by dialing 800-642-1687 (United States and Canada) or 706-645-9291 (International) and typing in the passcode 7704837 from April 27, 2006 at 5:30 p.m. Eastern Time until May 4, 2006.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics’ focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs its PUMA(TM) system and Cytometrix(TM) technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and may therefore be less likely to give rise to clinical side effects. Cytokinetics and GlaxoSmithKline (GSK) have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. Ispinesib (SB- 715992), SB-743921 and GSK-923295 are being developed under the strategic alliance with GSK. GSK is conducting Phase II and Ib clinical trials for ispinesib and GSK and Cytokinetics are each conducting a Phase I clinical trial for SB-743921. Cytokinetics’ unpartnered cardiovascular disease program is the second program to leverage the company’s expertise in cytoskeletal pharmacology. Cytokinetics is conducting a Phase I clinical trial with CK- 1827452, a novel small molecule cardiac myosin activator, for the intravenous treatment of heart failure and has also selected CK-1827452 as a potential drug candidate for the treatment of chronic heart failure via oral administration. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding the potential benefits of our drug candidates and potential drug candidates and the enabling capabilities of our proprietary technologies. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of Cytokinetics’ drug candidates that could slow or prevent clinical development, product approval or market acceptance (including the risks relating to uncertainty of patent protection for Cytokinetics’ intellectual property or trade secrets, Cytokinetics’ ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
Cytokinetics, Incorporated
CONTACT: Sharon Surrey-Barbari, Senior Vice President of Finance and CFOof Cytokinetics, Incorporated, +1-650-624-3000; or investors, Clay Kramer,Burns McClellan, Inc., or media, Justin Jackson, both of Burns McClellan,Inc., +1-212-213-0006
Web site: http://www.cytokinetics.com//
